| Cas9 activates the p53 pathway and selects for p53-inactivating mutations OM Enache, V Rendo, M Abdusamad, D Lam, D Davison, S Pal, ... Nature genetics 52 (7), 662-668, 2020 | 214 | 2020 |
| Somatic ephrin receptor mutations are associated with metastasis in primary colorectal cancer L Mathot, S Kundu, V Ljungström, J Svedlund, L Moens, T Adlerteg, ... Cancer research 77 (7), 1730-1740, 2017 | 37 | 2017 |
| Cancer aneuploidies are shaped primarily by effects on tumour fitness J Shih, S Sarmashghi, N Zhakula-Kostadinova, S Zhang, Y Georgis, ... Nature 619 (7971), 793-800, 2023 | 28 | 2023 |
| PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation P Khadka, ZJ Reitman, S Lu, G Buchan, G Gionet, F Dubois, DM Carvalho, ... Nature communications 13 (1), 604, 2022 | 26 | 2022 |
| Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N‐Acetyltransferase NAT2 LP Conway, V Rendo, MSP Correia, IA Bergdahl, T Sjöblom, D Globisch Angewandte chemie international edition 59 (34), 14342-14346, 2020 | 23 | 2020 |
| TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs N Parnandi, V Rendo, G Cui, MV Botuyan, M Remisova, H Nguyen, ... Molecular cell 81 (12), 2583-2595. e6, 2021 | 22 | 2021 |
| Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy V Rendo, I Stoimenov, A Mateus, E Sjöberg, R Svensson, AL Gustavsson, ... Nature communications 11 (1), 1308, 2020 | 20 | 2020 |
| Somatic PRDM2 c. 4467delA mutations in colorectal cancers control histone methylation and tumor growth T Pandzic, V Rendo, J Lim, C Larsson, J Larsson, I Stoimenov, S Kundu, ... Oncotarget 8 (58), 98646, 2017 | 17 | 2017 |
| Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis S Kundu, MA Ali, N Handin, LP Conway, V Rendo, P Artursson, L He, ... Journal of Experimental & Clinical Cancer Research 40, 1-19, 2021 | 15 | 2021 |
| Author correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations OM Enache, V Rendo, M Abdusamad, D Lam, D Davison, S Pal, ... Nature Genetics 52 (7), 748-749, 2020 | 13 | 2020 |
| Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer V Rendo, S Kundu, N Rameika, V Ljungström, R Svensson, K Palin, ... Scientific Reports 10 (1), 22436, 2020 | 5 | 2020 |
| Dna damage response signature guided rational design of crispr-based systems and therapies U Ben-David, T Golub, R Beroukhim, O Enache, V Rendo US Patent App. 17/148,477, 2021 | 2 | 2021 |
| CTNI-26. SURGICAL WINDOW OF OPPORTUNITY TRIAL OF NAVTEMADLIN (KRT 232; AMG232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA E Lee, M Rudek, V Rendo, N Khuu, T Walbert, M Holdhoff, F Lieberman, ... Neuro-Oncology 24 (Supplement_7), vii76-vii76, 2022 | 1 | 2022 |
| Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity X Zhang, E Akcan, M Correia, N Rameika, S Kundu, I Stoimenov, ... Biochemical Pharmacology 203, 115184, 2022 | 1 | 2022 |
| Women in cancer research and oncology J Joyce, H Wakelee, MB Davis, SH Teo, S Bell, V Rendo Cancer Cell 39 (3), 285-287, 2021 | 1 | 2021 |
| 978 Loss of heterozygosity in CYP2D6 locus sensitises cancer cells to talazoparib X Zhang, N Rameika, L Zhong, V Rendo, S Kundu, I Tsiara, D Globisch, ... International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | | 2024 |
| Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening H Gezelius, AP Enblad, A Lundmark, M Åberg, K Blom, J Rudfeldt, ... NAR Genomics and Bioinformatics 6 (1), lqae001, 2024 | | 2024 |
| SURGICAL WINDOW OF OPPORTUNITY TRIAL REVEALS MECHANISMS OF RESPONSE AND RESISTANCE TO NAVTEMADLIN (KRT-232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA V Rendo, E Lee, C Bossi, N Khuu, S Pal, A Reynolds, A Fassinou, K Ligon, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| 2307P Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy N Rameika, X Zhang, L Zhong, V Rendo, S Kundu, S Nuciforo, ... Annals of Oncology 34, S1179, 2023 | | 2023 |
| Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparib T Sjöblom, X Zhang, N Rameika, L Zhong, V Rendo, S Kundu, S Nuciforo, ... | | 2023 |
